



State of Louisiana

Louisiana Department of Health
Office of Public Health

DATE: January 6, 2022
TO: COVID-19 Vaccination Providers and all other HAN recipients
FROM: Louisiana Department of Health
SUBJECT: **New COVID-19 Vaccine Booster Dose/Additional Dose Guidance**

The Louisiana Department of Health (LDH) announces that, effective immediately:

- Individuals 12-17 years old are recommended to receive a booster shot 5 months after completion of their initial Pfizer-BioNTech vaccination series. At this time, only the Pfizer-BioNTech COVID-19 vaccine is authorized for 12-17-year-olds.
- The booster dose interval of six months after initial series completion has been shortened to **five months** for all individuals ages 12 years and older who completed the Pfizer-BioNTech COVID-19 vaccine initial series. This means that individuals can now receive an mRNA booster (Pfizer or Moderna) dose five months after completing the initial Pfizer-BioNTech series. The booster interval recommendation for people who initially received the J&J vaccine (two months) or the Moderna vaccine (six months) has not changed.
- Moderately or severely immunocompromised children ages 5-11 are eligible to receive an additional primary (or third) dose of vaccine 28 days after completing their second initial series vaccination. At this time, only the Pfizer-BioNTech COVID-19 vaccine is authorized for 5-11-year-olds. A description of what it means for a patient to be moderately or severely immunocompromised can be found at <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html>

Updated FDA Fact Sheet for Healthcare Providers, 12 years of age and older, purple cap (must dilute): <https://www.fda.gov/media/153713/download>

Updated FDA Fact Sheet for Healthcare Providers, 12 years of age and older, gray cap (no dilution): <https://www.fda.gov/media/153715/download>

Updated FDA Fact Sheet for Healthcare Providers, 5 - 11 years of age, orange cap (must dilute): <https://www.fda.gov/media/153714/download>

LDH reminds providers to report possible vaccine-related adverse events to the FDA/CDC Vaccine Adverse Event Reporting System (VAERS) at <https://vaers.hhs.gov/reportevent.html> or by calling 1-800-822-7967. Any possible severe adverse events (those resulting in hospitalization, death, or persistent disability) should be immediately reported to the Office Public Health (OPH) Infectious Disease/Epidemiology Hotline at 1-800-256-2748.

If you have vaccine related questions, please contact la.immunization@la.gov